Contact | Print version | PDF version | Send article | RSS-Feed

Ablynx announces senior management change

02 May 2008 - Ablynx has announced that Dr Hennie Hoogenboom will be stepping down from his position as Chief Scientific Officer and member of the Executive Committee.
 
Dr Hoogenboom joined Ablynx in 2005 and has contributed significantly to building up the robust Nanobody® technology platform and to the discovery of Nanobodies® for internal and partnered therapeutic programmes, according to the company. Dr Hoogenboom will work closely together with the Executive Committee to assure an effective and smooth transition of responsibilities.
 
Dr Edwin Moses, Chief Executive Officer and Chairman commented: "I wish to thank Hennie for his contribution to Ablynx. We appreciate his contributions and wish him well in his future endeavors." In line with its strategy to transition from a technology platform to a product Company, Ablynx has initiated an executive search to strengthen its senior management team with individuals with extensive experience in the discovery and development of pharmaceuticals. Commenting on this search, Dr Moses said: "With its extensive resources, excellent validated biologics platform technology and developing product pipeline, Ablynx offers unique opportunities to the right individuals."
 
As the Company continues to advance its product portfolio to grow a broader product pipeline, its aim is to file 5 IND-equivalents over the next 5 years. Ablynx's lead programme, ALX-0081 has successfully completed a first Phase I study and the Company is progressing this development candidate to the next stage, with a Phase 1b multi-dose study in patients due to start shortly.